Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Year Ended December 31, 2018
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	4,131,000	$	262,000	$	--	$	4,393,000
BioArchive		1,792,000		1,306,000		--		3,098,000
Manual Disposables		976,000		--		--		976,000
CAR-TXpress		907,000		--		--		907,000
Other		--		--		95,000		95,000
Total Device Segment		7,806,000		1,568,000		95,000		9,469,000
Clinical Development Segment:
Bone Marrow		--		135,000		--		135,000
Other		38,000		30,000		--		68,000
Total Clinical Development		38,000		165,000		--		203,000
Total	$	7,844,000	$	1,733,000	$	95,000	$	9,672,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	2019		2020		2021		2022 and beyond		Total
Service revenue	$	1,035,000	$	369,000	$	112,000			$	1,516,000
Clinical revenue		14,000		14,000		14,000	$	210,000		252,000
Total	$	1,049,000	$	383,000	$	126,000	$	210,000	$	1,768,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	December 31,		December 31,		June 30,
	2018		2017		2017
Common stock equivalents of convertible promissory note and accrued interest		48,405,556		--		--
Vested Series A warrants		404,412		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529		698,529
Warrants – other		16,162,267		3,725,782		3,725,782
Stock options		3,023,639		1,156,027		397,388
Restricted stock units		--		416		59,694
Total		68,694,403		5,985,166		5,285,805